Can new computer software technology be used to help place the pacing lead on the left side of the heart in the most beneficial position when a participant has a cardiac resynchronisation therapy device (CRT-D) implant?

A prospective randomised multi-centre Trial comparing cArdiac MRI guided CRT versus Conventional CRT implantation in patients with Ischaemic Cardiomyopathy - TACTIC CRT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91522248

Enrollment

218

Registered

2019-07-02

Start date

2019-07-05

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemic cardiomyopathy Circulatory System Ischaemic cardiomyopathy

Interventions

Patients in this study receiving CRT will be randomly assigned to either an ‘advanced technology’ arm or a conventional treatment arm. In the advanced technology arm, cardiac MR scans

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. >= 18 years of age 2. Standard indication for CRT-P or CRT-D according to ESC/EHRA guidelines 3. Stable on optimal medical therapy for at least 3 months 4. Ischaemic aetiology 5. Patients with atrial fibrillation can be included

Exclusion criteria

Exclusion criteria: 1. Any contraindication to pacing/implantable cardioverter-defibrillator (ICD) implant 2. Requirement for endocardial pacing 3. Contraindication to magnetic resonance (MR) scanning 4. Claustrophobia 5. Significant renal impairment with estimated glomerular filtration rate (eGFR) < 30 ml/minute 6. Existing pacemaker or ICD system or extraction of a CRT system within the last 6 months 7. Be pregnant or plan to become pregnant over the next 7 months 8. Participation in other studies

Design outcomes

Primary

Measure	Time frame
End systolic volume (ESV) in (ml) measured using a 2D echocardiogram at baseline and 6 months	—

Secondary

Measure	Time frame
1. End diastolic volume (ESV) in (ml) measured using a 2D echocardiogram at baseline and 6 months 2. Ejection fraction (%) measured using a 2D echocardiogram at baseline and 6 months 3. Quality of life measured using a Minnesota Living with Heart Failure Questionnaire score at baseline and 6 months 4. Efficacy of device implant measured using clinical composite score at 6 months 5. Class of heart failure measured using NYHA class at baseline and 6 months	—

Measure

Time frame

1. End diastolic volume (ESV) in (ml) measured using a 2D echocardiogram at baseline and 6 months 2. Ejection fraction (%) measured using a 2D echocardiogram at baseline and 6 months 3. Quality of life measured using a Minnesota Living with Heart Failure Questionnaire score at baseline and 6 months 4. Efficacy of device implant measured using clinical composite score at 6 months 5. Class of heart failure measured using NYHA class at baseline and 6 months

—

Countries

United Kingdom

Contacts

Public ContactMatthew Osmond

Matthew.osmond@gstt.nhs.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026